Novo Nordisk Faces a Three-Part Test: Doctor Data Questions, a Pediatric Insulin Approval and a Buyback in Progress
Published on 10/26/2026 at 03:10 | Editorial boerse-global.de
Novo Nordisk is under pressure to explain itself on an unusual front. Danish medical and nursing associations are demanding answers about an internal company list that classifies healthcare professionals, according to a report published Friday. The directory became public after a cyberattack, and it sorts clinicians by how likely they are to prescribe Novo Nordisk medicines, along with their familiarity with those drugs.
Investors now have a second information file to weigh alongside the drug pipeline. The distinction matters: the cyberattack exposed the list, while the associations' demands concern the list itself. Neither yields a legal verdict on the directory nor an estimate of financial damage. What the dispute does touch is how the company handles data about the people who write its prescriptions — a governance question, not a read on any product's efficacy.
A regulatory green light, with a narrower label than it first appears
On the operational side, the company won FDA approval for Awiqli to improve blood sugar control in children aged ten and older with type 2 diabetes. Novo Nordisk calls it the first once-weekly insulin cleared for this pediatric use. The practical effect is a sharp cut in injection burden: seven basal insulin shots a week become one.
That is a regulatory decision, and it stands apart from the clinical-stage work. CagriSema remains an investigational drug, and the data released Tuesday came from post-hoc analyses of the Phase 3 REDEFINE 1 trial.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The CagriSema numbers carry their own asterisks
Among 2,309 women with overweight or obesity, and assuming sustained treatment, the average weight loss reached 25.0% through week 68. The placebo group lost 3.0%. Novo Nordisk explicitly labeled these analyses exploratory and hypothesis-generating — a subgroup finding, not the trial's headline result.
The full study, covering more than 3,400 adults, showed average weight loss of 22.7%, short of the company's own 25% target. Reuters reported share gains after the additional analysis was published.
Buybacks: a ledger, not a finish line
Capital returns tell a third story. Novo Nordisk reported further repurchases on 19 October under a program worth up to DKK 15 billion over twelve months from 4 February. By 16 October, the company had bought back 39,074,179 B shares for a total of DKK 10,875,024,304.
Those figures describe progress, not completion. The gap between the program's ceiling and what has actually been executed is the number to watch, and repurchases answer a different investor question than the upcoming accounts do — they document capital deployed into the company's own stock, not how the underlying business performed.
Three signals, three separate yardsticks
The threads do not combine into a single verdict. Awiqli has a regulatory decision behind it; CagriSema, despite the stronger showing in the female subgroup, remains a candidate drug; the buyback records spending rather than proving operational momentum; and the physician directory raises questions about data handling that sit outside the science altogether.
The next independent checkpoint arrives on 4 November, when Novo Nordisk reports third-quarter 2026 results. That release, rather than any of the above, will show how the business itself has been tracking.
Ad
Novo Nordisk Stock: New Analysis - 26 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
